At close: 4:00:00 PM EST
After hours: 4:32:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,640,348.00
1,243,336.00
933,013.00
701,887.00
540,099.00
Cost of Revenue
230,971.00
150,343.00
139,989.00
97,049.00
63,382.00
Gross Profit
1,409,377.00
1,092,993.00
793,024.00
604,838.00
476,717.00
Operating Expense
1,328,352.00
1,360,817.00
1,329,225.00
1,054,548.00
1,040,880.00
Operating Income
81,025.00
-267,824.00
-536,201.00
-449,710.00
-564,163.00
Net Non Operating Interest Income Expense
60,550.00
63,959.00
-25,525.00
-63,014.00
-56,977.00
Other Income Expense
-12,173.00
-316,233.00
-128,237.00
93,776.00
68,075.00
Pretax Income
129,402.00
-520,098.00
-689,963.00
-418,948.00
-553,065.00
Tax Provision
7,557.00
15,879.00
13,525.00
-168.00
1,063.00
Net Income Common Stockholders
121,845.00
-535,977.00
-703,488.00
-418,780.00
-554,128.00
Diluted NI Available to Com Stockholders
123,027.00
-535,977.00
-703,488.00
-418,780.00
-554,128.00
Basic EPS
1.56
-5.80
-8.03
-5.15
-7.11
Diluted EPS
1.54
-5.80
-8.03
-5.15
-7.11
Basic Average Shares
96,943.00
92,398.00
87,559.00
81,262.00
77,956.00
Diluted Average Shares
100,620.25
92,398.00
87,559.00
81,262.00
77,956.00
Total Operating Income as Reported
81,025.00
-267,824.00
-536,201.00
-459,710.00
-564,163.00
Total Expenses
1,559,323.00
1,511,160.00
1,469,214.00
1,151,597.00
1,104,262.00
Net Income from Continuing & Discontinued Operation
121,845.00
-535,977.00
-703,488.00
-418,780.00
-554,128.00
Normalized Income
132,263.81
-205,085.50
-607,648.36
-411,492.00
-521,278.00
Interest Income
79,700.00
85,969.00
27,723.00
511.00
2,970.00
Interest Expense
19,150.00
22,010.00
53,248.00
63,525.00
59,947.00
Net Interest Income
60,550.00
63,959.00
-25,525.00
-63,014.00
-56,977.00
EBIT
148,552.00
-498,088.00
-636,715.00
-355,423.00
-493,118.00
EBITDA
187,193.00
-453,691.00
-594,851.00
-317,406.00
-466,207.00
Reconciled Cost of Revenue
194,897.00
107,505.00
98,839.00
59,738.00
37,133.00
Reconciled Depreciation
38,641.00
44,397.00
41,864.00
38,017.00
26,911.00
Net Income from Continuing Operation Net Minority Interest
121,845.00
-535,977.00
-703,488.00
-418,780.00
-554,128.00
Total Unusual Items Excluding Goodwill
-11,065.00
-418,850.00
-121,316.00
-7,288.00
-45,000.00
Total Unusual Items
-11,065.00
-418,850.00
-121,316.00
-7,288.00
-45,000.00
Normalized EBITDA
198,258.00
-34,841.00
-473,535.00
-310,118.00
-421,207.00
Tax Rate for Calcs
0.00
0.00
0.00
--
0.00
Tax Effect of Unusual Items
-646.19
-87,958.50
-25,476.36
--
-12,150.00
12/31/2020 - 6/4/1997
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ALNY Alnylam Pharmaceuticals, Inc.
237.98
-1.07%
ARWR Arrowhead Pharmaceuticals, Inc.
18.49
-6.38%
BMRN BioMarin Pharmaceutical Inc.
67.38
-1.46%
IONS Ionis Pharmaceuticals, Inc.
33.46
-1.88%
INCY Incyte Corporation
70.54
-3.54%
LEGN Legend Biotech Corporation
33.62
+2.59%
BPMC Blueprint Medicines Corporation
87.43
-3.53%
AXSM Axsome Therapeutics, Inc.
80.05
-3.05%
MDGL Madrigal Pharmaceuticals, Inc.
338.91
+1.66%
BLUE bluebird bio, Inc.
8.46
0.00%